Merck has secured FDA approval for LIPFENDRA (enlicitide) 20 mg tablets, establishing the first oral PCSK9 inhibitor available for the management of hypercholesterolemia. Approved as an adjunct to diet and exercise, the macrocyclic peptide is indicated for adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). Also read: CMS Proposes Major Medicare Overhaul: Shifting Toward Accountable Care and Value-Based Payments The therap

Takeda Reports Positive Phase 3 Results for Zasocitinib in Plaque Psoriasis Takeda Pharmaceutical has announced positive results from its pivotal Phase 3 LATITUDE PsO 3001 and 3002 clinical trials, establishing its selective TYK2 inhibitor, zasocitinib, as a high-efficacy oral candidate for moderate-to-severe plaque psoriasis. With approximately 70 percent of participants achieving a static Physician Global Assessment (sPGA) score of clear or almost clear by the 16-week mark,